Neuronal bungarotoxin blocks the nicotinic stimulation of endogenous dopamine release from rat striatum
References (26)
- et al.
Localization of α-bungarotoxin binding sites in mouse brain by light and electron microscopic autoradiography
Brain Res.
(1978) - et al.
Nicotine-induced release of catecholamines from rat hippocampus and striatum
Biochem. Pharmacol.
(1978) - et al.
Dissociation of α-bungarotoxin binding and receptor block in the rat superior cervical ganglion
Brain Res.
(1977) - et al.
Autoradiographic distribution of nicotine receptors in rat brain
Brain Res.
(1984) - et al.
Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons
Brain Res.
(1985) - et al.
Biochemical evidence for the presence of presynaptic receptors on dopaminergic nerve terminals
Brain Res.
(1978) Effects of nicotine on distribution and release of [14C]-norepinephrine and [14C]-dopamine in rat brain striatum and hypothalamus slices
Neuropharmacology
(1974)- et al.
Some observations on the binding patterns of α-bungarotoxin in the central nervous system of the rat
Brain Res.
(1978) - et al.
Characterization of a snake venom neurotoxin which blocks nicotinic transmission in the avian ciliary ganglion
Neuroscience
(1984) - et al.
Characterization of neuronal nicotinic receptors by snake venom neurotoxins
Trends Neurosci.
(1988)
The ultrastructural distribution of putative nicotinic receptors on cultured neurons from the rat superior cervical ganglion
Neuroscience
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
Enhancement of [3H]dopamine release and its [3H]metabolites in rat striatum by nicotinic drugs
Brain Res.
Cited by (67)
Nicotinic receptor-based therapeutics and candidates for smoking cessation
2009, Biochemical PharmacologyCitation Excerpt :A major role for α6 and β3 in nicotine-evoked DA release in striatum is based on both knockout and gain-of-function studies [71,72]; these subunits are highly expressed in substantia nigra and the ventral tegmental area (VTA) [25,27,64,71,73]. α-Conotoxin MII (α-CtxMII) inhibits nicotine-evoked [3H]DA release from striatal preparations [74–78]. Although α-CtxMII was thought to be a selective antagonist for α3-containing subtypes, the finding that 125I-α-CtxMII binding remains in α3 knockout mice, but is abolished in α6 knockouts, provides supports that α-CtxMII is a selective antagonist at α6-containing nAChRs [79–81].
Nicotine-induced upregulation of nicotinic receptors: Underlying mechanisms and relevance to nicotine addiction
2009, Biochemical PharmacologyCitation Excerpt :Studies using immunoprecipitation with subunit-specific antibodies have shown that nicotinic receptors containing α4 and β2 subunits predominate in striatal preparations [67]. However, the nicotinic receptor antagonists nBgt [68,69] and α-Conotoxin MII [70,71], block ∼50% of the nicotine-stimulated DA release in striatal slice and synaptosomal preparations, while αBgt fails to block release altogether. Autoradiography and binding experiments using 125I-nBgt [53,54] or 125I-α-Conotoxin MII [72] have shown labeling in these areas.
tris-Azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release
2007, Bioorganic and Medicinal Chemistry LettersNeurochemical alterations produced by daily nicotine exposure in periadolescent vs. adult male rats
2004, European Journal of PharmacologySubtype-selective nicotinic receptor antagonists: Potential as tobacco use cessation agents
2004, Bioorganic and Medicinal Chemistry LettersNicotine and nicotinic receptors; relevance to Parkinson's disease
2002, NeuroToxicology